Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402025 · ClinicalTrials.gov registry record · Phase 1
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
A Phase 1 study of Pancreatic Cancer, sponsored by BioVex Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 3
- Study locations
NCT00402025 is a Phase 1 study of Pancreatic Cancer that has completed, run by BioVex Limited. The registered enrollment target is 17 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00402025, a Phase 1 study of Pancreatic Cancer, has completed, sponsored by BioVex Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to assess the safety of injections of talimogene laherparepvec into patients with pancreatic cancer that cannot be removed by surgery. The study will also test whether the injections are effective in treating the tumor.
Conditions Studied
Interventions
- BIOLOGICAL Talimogene Laherparepvec
Study Locations (3)
California
- UCI Medical Center - Orange
- California Pacific Medical Center - San Francisco
Texas
- Mary Crowely Medical Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402025
The ClinicalTrials.gov registry entry for NCT00402025 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The listed sponsor is BioVex Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Talimogene Laherparepvec is the first listed.
NCT00402025 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT00402025 about?
NCT00402025 is a clinical study titled "Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer". The purpose of the study is to assess the safety of injections of talimogene laherparepvec into patients with pancreatic cancer that cannot be removed by surgery. The study will also test whether the injections are effective in treating the tumor.
What is the current status of trial NCT00402025?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2006-11. Estimated completion is 2008-01.
What conditions does trial NCT00402025 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00402025?
The interventions under investigation include: Talimogene Laherparepvec (BIOLOGICAL).
Who is sponsoring clinical trial NCT00402025?
This trial is sponsored by BioVex Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00402025 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.